Arrowstreet Capital’s Utah Medical Products UTMD Stock Holding History

Arrowstreet Capital’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368K	Hold	5,328	–	–	﹤0.01%	1786
2026 Q1	$330K	Hold	5,328	–	–	﹤0.01%	1722
2025 Q4	$298K	Hold	5,328	–	–	﹤0.01%	1735
2025 Q3	$336K	Hold	5,328	–	–	﹤0.01%	1749
2025 Q2	$303K	Hold	5,328	–	–	﹤0.01%	1834
2025 Q1	$299K	Hold	5,328	–	–	﹤0.01%	1686
2024 Q4	$328K	Sell	5,328 -596	-10%	-$38.5K	﹤0.01%	1609
2024 Q3	$396K	Buy	+5,924	New	+$402K	﹤0.01%	1552
2021 Q1	–	Sell	-5,100	Closed	-$430K	–	2550
2020 Q4	$430K	Buy	5,100 +1,500	+42%	+$128K	﹤0.01%	2045
2020 Q3	$288K	Buy	+3,600	New	+$299K	﹤0.01%	2147

Other funds holding UTMD

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital's UTMD Position: Q2 2026 in Review

Arrowstreet Capital held its Utah Medical Products (UTMD) position steady in Q2 2026 at 5,328 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

Arrowstreet Capital first reported a position in UTMD in Q3 2020 and has held it in 10 quarters since. The position peaked at $430K in Q4 2020. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

Arrowstreet Capital held 5,328 shares of Utah Medical Products worth $368K as of Q2 2026.
Arrowstreet Capital left its Utah Medical Products share count unchanged in Q2 2026.
Utah Medical Products made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1786 holding.
Arrowstreet Capital first reported a position in Utah Medical Products in Q3 2020 and has held it in 10 quarters since.
Arrowstreet Capital's Utah Medical Products position peaked at $430K in Q4 2020.
114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.